Entero Therapeutics Stock Quote ENTO - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.400001

Bid

0.4101

Ask

0.4196

Volume

13,847

0.398 Day's Range 0.42

0.185 52 Week Range 3.16

Previous Close

0.400989

Open

0.398

Last Trade

0.4098

Last Trade Time

10:46:14

Average Volume (3m)

423,708

Financial Volume

$ 5,597

VWAP

0.404206

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.214999	-34.9591869919	0.615	0.615	0.38	195854	0.4854591	CS
4	-0.228999	-36.406836248	0.629	0.75	0.38	211013	0.5991807	CS
12	-0.038999	-8.88359908884	0.439	0.8655	0.28	423708	0.56309168	CS
26	-2.419999	-85.8155673759	2.82	2.99	0.185	476674	0.47603891	CS
52	-2.559999	-86.4864527027	2.96	3.16	0.185	469533	0.4773361	CS
156	-2.559999	-86.4864527027	2.96	3.16	0.185	469533	0.4773361	CS
260	-2.559999	-86.4864527027	2.96	3.16	0.185	469533	0.4773361	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WORXSCWorx Corporation	$ 1.93 (96.94%)	103.79M
CRNCCerence Inc	$ 5.0099 (77.66%)	31.16M
BDRXBiodexa Pharmaceuticals PLC	$ 6.8101 (76.89%)	1.49M
IBGInnovation Beverage Group Limited	$ 1.10 (39.03%)	6.22M
SPAISafe Pro Group Inc	$ 4.37 (36.56%)	38.23M
PYXSPyxis Oncology Inc	$ 2.06 (-46.07%)	9.15M
KURAKura Oncology Inc	$ 9.865 (-37.99%)	7.4M
BLRXBioLineRx Ltd	$ 0.3585 (-34.24%)	5.6M
GLXGGalaxy Payroll Group Ltd	$ 2.60 (-33.50%)	387.24k
SHOTWSafety Shot Inc	$ 0.1001 (-33.27%)	2.5k
CDTConduit Pharmaceuticals Inc	$ 0.111999 (21.34%)	486.12M
NVDANVIDIA Corporation	$ 143.9509 (-1.33%)	198.63M
AKTSAkoustis Technologies Inc	$ 0.0999 (14.70%)	181.9M
ELABElevai Labs Inc	$ 0.0202 (-5.61%)	135.79M
WORXSCWorx Corporation	$ 1.93 (96.94%)	103.79M